Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated ...

Regeneron submitted regulatory applications to the FDA for Eylea HD pre-filled syringe and had positive phase 3 clinical ...

SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales. Total Libtayo sales came in at $366.9 million, up 50% year ...

Regeneron Pharmaceuticals ... injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

Regeneron submitted regulatory applications to the FDA for Eylea HD pre-filled syringe and had positive phase 3 clinical trial results in retinal vein occlusion (RVO). Libtayo's year 2024 sales ...

Regeneron Pharmaceuticals reported fourth-quarter ... collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the Zacks Consensus Estimate ...